Swedish Online Retail and Ecommerce Stock News

OM:SWED A
OM:SWED ABanks

Assessing Swedbank (OM:SWED A) Valuation After Launch Of New Share Buyback Program

Swedbank launches buyback program Swedbank (OM:SWED A) has kicked off a share repurchase program authorized at its March 2025 AGM, committing SEK 1,100 million to buy 2,000,000 shares, or 0.17% of issued capital. See our latest analysis for Swedbank. Swedbank’s latest buyback arrives after a 21.09% 90 day share price return and a 46.74% 1 year total shareholder return. This suggests recent momentum has been building even as the 7 day share price return has been softer. If this buyback has you...
OM:ASSA B
OM:ASSA BBuilding

A Look At ASSA ABLOY (OM:ASSA B) Valuation After Earnings, Dividend Proposal And New Smart Lock Launches

ASSA ABLOY (OM:ASSA B) shares are in focus after a packed early February, with the group reporting 2025 results, proposing a higher dividend, and highlighting new professional smart lock launches under the Yale and Master Lock brands. See our latest analysis for ASSA ABLOY. Those February announcements appear to sit against a share price that has eased in the very short term, with a 1-day share price return of 0.50% decline and a 7-day share price return of 2.93% decline. However, the 90-day...
OM:EVO
OM:EVOHospitality

Assessing Evolution (OM:EVO) Valuation After Weaker Q4 And Full Year 2025 Earnings

Why Evolution’s latest earnings matter for shareholders Evolution (OM:EVO) has come under closer scrutiny after reporting its fourth quarter and full year 2025 results, with both revenue and net income lower than the prior year. This has prompted fresh questions about the stock’s recent slide. See our latest analysis for Evolution. The share price has retreated to SEK523.6, with a 1-day share price decline of 2.42% and a year-to-date share price decline of 16.12%, while the 1-year total...
OM:VSURE
OM:VSURECommercial Services

Assessing Verisure (OM:VSURE) Valuation After Q4 2025 Sales Growth And Wider Net Losses

Balancing higher sales and wider losses Verisure (OM:VSURE) has drawn fresh attention after reporting Q4 and full year 2025 results, with sales of €964.7 million in the quarter and €3.7b for the year alongside wider net losses. That mix of higher revenue and larger losses gives you a lot to weigh up, especially given the stock’s recent negative returns over the month and past 3 months. Here is how those headline figures fit together. See our latest analysis for Verisure. Verisure’s latest...
OM:TEQ
OM:TEQTrade Distributors

Teqnion (OM:TEQ) Earnings Loss And Margin Squeeze Challenge Premium P/E Narratives

Teqnion (OM:TEQ) has just posted a mixed set of FY 2025 figures, with Q3 revenue at SEK455.6 million and a basic EPS loss of SEK1.31, while trailing 12 month revenue stands at SEK1,742.1 million and EPS at SEK3.79 as one off gains and weaker profitability in the most recent year filter through the numbers. Over recent quarters the company has seen revenue move from SEK381.8 million in Q3 2024 to SEK405.7 million in Q4 2024, then up to SEK406.3 million in Q1 2025 and SEK474.5 million in Q2...
OM:KARNEL B
OM:KARNEL BIndustrials

Karnell Group (OM:KARNEL B) Net Margin Expansion Tests Cautious Earnings Narratives

Karnell Group (OM:KARNEL B) has put up a busy FY 2025 so far, with Q3 revenue of SEK436 million and EPS of SEK0.88 setting the tone against a backdrop of trailing 12 month EPS of SEK2.52 and revenue of SEK1.63 billion, alongside reported earnings growth of 129.6% year on year. The company has seen quarterly revenue move from SEK356.6 million in Q3 2024 to SEK402.9 million in Q4 2024 and then SEK436 million in Q3 2025, while EPS has shifted from SEK0.55 to SEK0.57 and then SEK0.88 over the...
OM:YUBICO
OM:YUBICOSoftware

Yubico (OM:YUBICO) Net Margin Compression Challenges Bullish Growth Narratives

Yubico (OM:YUBICO) FY 2025 earnings snapshot Yubico (OM:YUBICO) has wrapped up FY 2025 with Q4 revenue of 548.3 million SEK and basic EPS of 0.04 SEK, setting the tone for a year where trailing 12 month revenue came in at 2.2 billion SEK and basic EPS was 1.49 SEK. The company has seen quarterly revenue move between 499.1 million SEK and 623.1 million SEK over the past year, with basic EPS ranging from 0.04 SEK to 0.74 SEK. Trailing 12 month EPS and net income have tracked alongside 12 month...
OM:VSURE
OM:VSURECommercial Services

Verisure (OM:VSURE) Q4 Loss Worsens To €121.3m Challenging Bullish Profitability Narratives

Verisure (OM:VSURE) FY 2025 Earnings Snapshot Verisure (OM:VSURE) has wrapped up FY 2025 with fourth quarter revenue of €964.7 million and a basic EPS loss of €0.12, while trailing 12 month figures show revenue of about €3.7 billion and a basic EPS loss of €0.30. Over the past year, the company has seen revenue move from €870.2 million in Q4 2024 to €964.7 million in Q4 2025, while quarterly EPS stayed in loss making territory, shifting from a €0.07 loss per share in Q4 2024 to a €0.12 loss...
OM:EQT
OM:EQTCapital Markets

Is There Now An Opportunity In EQT (OM:EQT) After The Recent 30 Day Pullback

If you are looking at EQT and wondering whether the current share price still offers value, this article will walk you through what the numbers actually say about the stock. The share price last closed at SEK 290.30, with returns of 2.0% over 7 days, a 19.4% decline over 30 days, and returns of 20.7% over 3 years and 21.8% over 5 years that give useful longer term context. Recent coverage of EQT has focused on how the stock's shorter term pullback sits against its longer term record. This...
OM:CAMX
OM:CAMXPharmaceuticals

Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress

Camurus AB reported its fourth-quarter and full-year 2025 results, with full-year sales rising to SEK 2,265.38 million and net income to SEK 735.57 million, while issuing 2026 guidance for revenues of SEK 2.60–2.90 billion and operating result of SEK 0.90–1.20 billion. Alongside these results, Camurus highlighted 2025 milestones including EU and UK approvals for Oxyesa in acromegaly and progress in long-acting metabolic therapies, underlining how its product pipeline and regulatory traction...
OM:VIMIAN
OM:VIMIANMedical Equipment

Global Stocks Trading Below Estimated Value In February 2026

As global markets navigate a period of mixed performance, with technology stocks facing challenges and value-oriented segments gaining traction, investors are keenly observing the shifts in economic indicators such as cooling U.S. labor data and fluctuating manufacturing activity. In this context, identifying undervalued stocks can be particularly appealing as they may offer potential opportunities for growth amidst the broader market volatility and sector rotations.